Current perspective on eicosanoids in asthma and allergic diseases - EAACI Task Force consensus report, part I.
- Sokolowska M Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.
- Rovati GE Department of Pharmaceutical Sciences, University of Milan, Italy.
- Diamant Z Department of Respiratory Medicine & Allergology, Skane University Hospital, Lund, Sweden.
- Untersmayr E Institute of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.
- Schwarze J Child Life and Health and Centre for Inflammation Research, The University of Edinburgh, Edinburgh, UK.
- Lukasik Z Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.
- Sava F London North Genomic Laboratory Hub, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK.
- Angelina A Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.
- Palomares O Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University, Madrid, Spain.
- Akdis C Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland.
- O'Mahony L Departments of Medicine and Microbiology, APC Microbiome Ireland, University College Cork, Cork, Ireland.
- Sanak M Department of Medicine, Jagiellonian University Medical College, Krakow, Poland.
- Dahlen SE Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden.
- Woszczek G MRC/Asthma UK Centre in Allergic Mechanisms of Asthma, School of Immunology & Microbial Sciences, King's College London, London, UK.
- 2020-04-13
Published in:
- Allergy. - 2020
English
Eicosanoids are biologically active lipid mediators, comprising prostaglandins, leukotrienes, thromboxanes and lipoxins, involved in several pathophysiological processes relevant to asthma, allergies and allied diseases. Prostaglandins and leukotrienes are the most studied eicosanoids and established inducers of airway pathophysiology including bronchoconstriction and airway inflammation. Drugs inhibiting the synthesis of lipid mediators or their effects, such as leukotriene synthesis inhibitors, leukotriene receptors antagonists, and more recently prostaglandin D2 receptor antagonists, have been shown to modulate features of asthma and allergic diseases. This review, produced by an European Academy of Allergy and Clinical Immunology (EAACI) task force, highlights our current understanding of eicosanoid biology and its role in mediating human pathology, with a focus on new findings relevant for clinical practice, development of novel therapeutics, and future research opportunities.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1111/all.14295
- PMID 32279330
- Persistent URL
- https://sonar.ch/global/documents/54201
Statistics
Document views: 7
File downloads:
- fulltext.pdf: 0